These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15170021)

  • 21. Pharmacological management of breathlessness in COPD: recent advances and hopes for the future.
    O'Donnell DE; Webb KA; Harle I; Neder JA
    Expert Rev Respir Med; 2016 Jul; 10(7):823-34. PubMed ID: 27115291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD.
    Ramlal SK; Visser FJ; Hop WC; Dekhuijzen PN; Heijdra YF
    Pulm Pharmacol Ther; 2014 Aug; 28(2):158-64. PubMed ID: 24076367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
    Brusasco V; Hodder R; Miravitlles M; Korducki L; Towse L; Kesten S
    Thorax; 2003 May; 58(5):399-404. PubMed ID: 12728159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Salmeterol in smokers with COPD.
    Lipworth BJ
    Thorax; 1996 Jan; 51(1):110. PubMed ID: 8658361
    [No Abstract]   [Full Text] [Related]  

  • 25. Assessing mortality risk in COPD.
    Richie RC
    J Insur Med; 2008; 40(1):55-63. PubMed ID: 18924368
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-acting beta(2) agonists as potential option in the treatment of acute exacerbations of COPD.
    Cazzola M; Matera MG
    Pulm Pharmacol Ther; 2003; 16(4):197-201. PubMed ID: 12850121
    [No Abstract]   [Full Text] [Related]  

  • 27. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
    Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Rousseau R;
    BMC Pulm Med; 2006 Feb; 6():3. PubMed ID: 16460562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined salmeterol and fluticasone for COPD.
    Vassiliou V
    Lancet; 2003 May; 361(9369):1651; author reply 1652-3. PubMed ID: 12747901
    [No Abstract]   [Full Text] [Related]  

  • 29. [Lung function and exercise tolerance after treatment with salmeterol or ipratropium bromide in chronic obstructive pulmonary disease].
    Grzanka A; Pitsch T; Krzywiecki A; Rogala B
    Pol Merkur Lekarski; 2004 Sep; 17(99):208-11. PubMed ID: 15628041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Airway blood flow reactivity in healthy smokers and in ex-smokers with or without COPD.
    Mendes ES; Campos MA; Wanner A
    Chest; 2006 Apr; 129(4):893-8. PubMed ID: 16608935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD.
    O'Donnell DE; Hamilton AL; Webb KA
    J Appl Physiol (1985); 2006 Oct; 101(4):1025-35. PubMed ID: 16675610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategies.
    Rabe KF
    Proc Am Thorac Soc; 2006 May; 3(3):270-5. PubMed ID: 16636097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stepping down therapy in COPD.
    Reilly JJ
    N Engl J Med; 2014 Oct; 371(14):1340-1. PubMed ID: 25196116
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparing dynamic hyperinflation and associated dyspnea induced by metronome-paced tachypnea versus incremental exercise.
    Calligaro GL; Raine RI; Bateman ME; Bateman ED; Cooper CB
    COPD; 2014 Feb; 11(1):105-12. PubMed ID: 24152211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment step down should be avoided at entry in COPD therapeutic trials.
    Marchand E
    Am J Respir Crit Care Med; 2008 Jul; 178(1):105-6; author reply 106-7. PubMed ID: 18565962
    [No Abstract]   [Full Text] [Related]  

  • 37. COPD: don't use fluticasone + salmeterol. Patients treated with inhaled fluticasone for chronic obstructive pulmonary disease (COPD) are more prone to pneumonia.
    Prescrire Int; 2007 Dec; 16(92):257-8. PubMed ID: 18092426
    [No Abstract]   [Full Text] [Related]  

  • 38. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB; Tillie-Leblond I; Attali V; Bavelele Z; Lagrange O
    Respir Med; 2011 Feb; 105(2):250-8. PubMed ID: 20702076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
    Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of death in COPD.
    Kupfer Y; Tessler S
    N Engl J Med; 2007 May; 356(21):2212-3; author reply 2213-4. PubMed ID: 17526086
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.